Hurricanes and heart failure: A review of the who, what, when, and where of beta-blocker therapy

Kathy Hebert, Lee Arcement, Ron Horswell

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

β-Blocker therapy has changed the landscape of treatment for chronic heart failure (HF). First recommended in published guidelines in 1999, the use of β-blockers has become the cornerstone of therapy. β-Blockers reduce both morbidity and mortality and also improve quality of life. This paper reviews and highlights the evidence supporting the current usage of β-blockers in HF. It also shares practical, real world tricks-of-the-trade regarding such usage drawn from 8 years of experience with over 3000 patients in eight safety net hospitals. Each hospital mentioned in this paper participates in an HF disease management program serving the needs of Louisiana's indigent population.

Original languageEnglish
Pages (from-to)89-95
Number of pages7
JournalCurrent Heart Failure Reports
Volume3
Issue number2
DOIs
StatePublished - Jun 1 2006

Fingerprint

Cyclonic Storms
Heart Failure
Safety-net Providers
Poverty
Disease Management
Heart Diseases
Therapeutics
Quality of Life
Guidelines
Morbidity
Mortality
Population

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)
  • Emergency Medicine

Cite this

Hurricanes and heart failure : A review of the who, what, when, and where of beta-blocker therapy. / Hebert, Kathy; Arcement, Lee; Horswell, Ron.

In: Current Heart Failure Reports, Vol. 3, No. 2, 01.06.2006, p. 89-95.

Research output: Contribution to journalArticle

Hebert, Kathy ; Arcement, Lee ; Horswell, Ron. / Hurricanes and heart failure : A review of the who, what, when, and where of beta-blocker therapy. In: Current Heart Failure Reports. 2006 ; Vol. 3, No. 2. pp. 89-95.
@article{62f69aadd76c42c9ac49407bd83d2005,
title = "Hurricanes and heart failure: A review of the who, what, when, and where of beta-blocker therapy",
abstract = "β-Blocker therapy has changed the landscape of treatment for chronic heart failure (HF). First recommended in published guidelines in 1999, the use of β-blockers has become the cornerstone of therapy. β-Blockers reduce both morbidity and mortality and also improve quality of life. This paper reviews and highlights the evidence supporting the current usage of β-blockers in HF. It also shares practical, real world tricks-of-the-trade regarding such usage drawn from 8 years of experience with over 3000 patients in eight safety net hospitals. Each hospital mentioned in this paper participates in an HF disease management program serving the needs of Louisiana's indigent population.",
author = "Kathy Hebert and Lee Arcement and Ron Horswell",
year = "2006",
month = "6",
day = "1",
doi = "10.1007/s11897-006-0007-9",
language = "English",
volume = "3",
pages = "89--95",
journal = "Current Heart Failure Reports",
issn = "1546-9530",
publisher = "Current Science, Inc.",
number = "2",

}

TY - JOUR

T1 - Hurricanes and heart failure

T2 - A review of the who, what, when, and where of beta-blocker therapy

AU - Hebert, Kathy

AU - Arcement, Lee

AU - Horswell, Ron

PY - 2006/6/1

Y1 - 2006/6/1

N2 - β-Blocker therapy has changed the landscape of treatment for chronic heart failure (HF). First recommended in published guidelines in 1999, the use of β-blockers has become the cornerstone of therapy. β-Blockers reduce both morbidity and mortality and also improve quality of life. This paper reviews and highlights the evidence supporting the current usage of β-blockers in HF. It also shares practical, real world tricks-of-the-trade regarding such usage drawn from 8 years of experience with over 3000 patients in eight safety net hospitals. Each hospital mentioned in this paper participates in an HF disease management program serving the needs of Louisiana's indigent population.

AB - β-Blocker therapy has changed the landscape of treatment for chronic heart failure (HF). First recommended in published guidelines in 1999, the use of β-blockers has become the cornerstone of therapy. β-Blockers reduce both morbidity and mortality and also improve quality of life. This paper reviews and highlights the evidence supporting the current usage of β-blockers in HF. It also shares practical, real world tricks-of-the-trade regarding such usage drawn from 8 years of experience with over 3000 patients in eight safety net hospitals. Each hospital mentioned in this paper participates in an HF disease management program serving the needs of Louisiana's indigent population.

UR - http://www.scopus.com/inward/record.url?scp=33750292509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750292509&partnerID=8YFLogxK

U2 - 10.1007/s11897-006-0007-9

DO - 10.1007/s11897-006-0007-9

M3 - Article

C2 - 16928342

AN - SCOPUS:33750292509

VL - 3

SP - 89

EP - 95

JO - Current Heart Failure Reports

JF - Current Heart Failure Reports

SN - 1546-9530

IS - 2

ER -